Sanne van Lith studied Biomedical Sciences at the Radboud university medical center, Nijmegen. She graduated cum laude in 2012 and started her PhD project at the Department of Pathology of the Radboud university medical center, Nijmegen. This project concerned tumor targeting with a llama antibody domain (VHH) based nanomedicine platform and unraveling and targeting of altered tumor metabolism in glioma and renal cell carcinoma. As of September 2017 she joined the Nuclear Medicine group as a postdoc researcher. She works under supervision of Martin Gotthardt, and her projects involve tracer development and implementation for imaging and treatment of diabetes and oncology.